Subcutaneous Amycretin Yields Promising Weight Loss in Phase ...
23 hours ago · On the other hand, those treated with placebo experienced an estimated 1.9%, 2.3%, and 2.0% body weight gain, respectively. Citing the positive effect of amycretin on weight loss, and its well-tolerated and consistent safety profile, Novo Nordisk announced plans for further clinical development of amycretin for overweight or obesity.
Novo Nordisk successfully completes phase 1b/2a trial with ...
12 hours ago · Amycretin is developed for oral and subcutaneous administration. About the Phase 1b/2a subcutaneous amycretin trial The trial was a randomised, placebo-controlled and double-blinded study assessing the safety, tolerability, pharmacokinetics, and proof-of-concept after subcutaneous administration of amycretin in people with overweight or obesity.
Novo Nordisk's next-gen obesity treatment hits target in ...
11 hours ago · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people adhered to treatment.
Amycretin - Wikipedia
Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.
Weight loss: Amycretin pill may be more effective than ...
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity —...
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
1 day ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo ...
Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain, rather than in the gut.
'Remarkable' Weight Loss With Novel Oral Combo in Phase 1
Sep 12, 2024 · Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.
Novo Nordisk’s Amylin Pill Is Fast-Acting, Longer Lasting ...
Sep 12, 2024 · Novo Nordisk is testing a new weight-loss pill, called amycretin, that is said to lead to faster, more significant weight loss than currently approved GLP-1 injectable medications like...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
- Some results have been removed